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Abstract
Purpose: In patients suffering from symptomatic peripheral artery disease (PAD), percutaneous revascularization is the
treatment of choice. However, restenosis may occur in 10 to 60% in the first year depending on a variety of factors. Small
dense low density lipoprotein (sdLDL) particles are associated with an increased risk for cardiovascular events, but their role
in the process of restenosis is not known. We conducted a prospective study to analyze the association of sdLDL particles
with the outcome of balloon angioplasty in PAD. The composite primary endpoint was defined as improved walking
distance and absence of restenosis.
Methods: Patients with angiographically documented PAD of the lower extremities who were scheduled for lower limb
revascularization were consecutively recruited for the study. At baseline and at three month follow-up triglyceride, total
cholesterol, LDL size and subclasses and HDL cholesterol and ankle-brachial index (ABI) were measured. Three months after
the intervention duplex sonography was performed to detect restenosis.
Results: Sixty-four patients (53% male) with a mean age of 68.669.9 years were included. The proportion of small- dense
LDL particles (class III and IV) was significantly lower (33.1611.0% vs. 39.4612.1%, p = 0.038) in patients who reached the
primary end-point compared with those who did not. Patients with improved walking distance and without restenosis had a
significantly higher LDL size at baseline (26.661.1 nm vs. 26.161.1 nm, p= 0.046) and at follow-up (26.761.1 nm vs.
26.260.9 nm, p = 0.044) than patients without improvement.
Conclusions: Small-dense LDL particles are associated with worse early outcome in patients undergoing percutaneous
revascularization for symptomatic PAD.
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Introduction
Peripheral artery disease (PAD) has a prevalence of up to 20%
in the elderly population [1]. The majority of patients are
asymptomatic [2]; therefore, early modification of risk factors is
mandatory to reduce the high rate of morbidity and mortality
associated with PAD [3].
Up to 10–35% of PAD patients are symptomatic [2], with
reduced quality of life due to pain and impaired mobility. The
presence of chronic wounds and critical ischemia may compromise
limb viability. Revascularization with angioplasty is an approved
therapeutic option to improve quality of life in patients with
intermittent claudication, and the treatment of choice in critical
limb ischemia. However, despite new devices and techniques,
restenosis is still a major problem, occurring in 10 to 60% of cases
after an initially technically successful angioplasty. The rate of
restenosis depends on a variety of factors, such as severity of the
PAD (i.e. claudication versus critical limb ischemia), the lesion type
(occlusion versus stenosis), the quality of both run-in and run-off
vessels, the length of the lesions but also on cardiovascular risk
factors [2,4,5], such as diabetes, hyperlipidemia, hypertension and
smoking.
Earlier publications have outlined the importance of low density
lipoprotein (LDL) size as a predictor of cardiovascular events and
progression of coronary artery disease [6]. The presence of small,
dense LDL (sdLDL) particles is an established cardiovascular risk
factor by the national Cholesterol Education Program Adult
treatment Panel III. sdLDL particle size is a predictive marker for
cardiovascular mortality in PAD patients [7], but its role in the
process of restenosis and clinical outcome in patients undergoing
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percutaneous revascularization is unclear. Therefore, we conduct-
ed a prospective study to investigate the potential role of sdLDL
particle as a predictor of early restenosis and adverse clinical
outcome after angioplasty with or without stenting.
Methods
Study design and patients
In this prospective, single-center, observational study, the effect
of sdLDL particles on restenosis and clinical outcome after
endovascular lower limb revascularization in PAD patients was
investigated.
Patients with atherosclerotic PAD, Fontaine I–III of the lower
limb, with or without a history of peripheral vascular intervention
or vascular surgery, who were scheduled for an intervention, were
consecutively recruited. Exclusion criteria were cardiac arrhyth-
mia, chronic inflammatory vascular disorders or failed revascu-
larization, defined as a more than 50% residual stenosis confirmed
angiographically or by duplex ultrasound after the procedure. All
examinations were performed at the study center (Clinic for
Angiology, University Hospital Zurich).
After baseline investigation patients underwent peripheral
angioplasty with plain balloon angioplasty, with or without
stenting (without drug-coated balloon or stent). The decision to
implant a stent was left to the operator, but patients receiving a
drug-eluting stent were excluded.
At baseline, body mass index (BMI), total cholesterol, LDL
cholesterol, HDL cholesterol, triglycerides, LDL-phenotype and
ankle-brachial index (ABI) were recorded. Details of other risk
factors and medication were recorded, and walking capacity was
evaluated using a walking questionnaire (SF-35). At three months
follow-up, LDL-phenotype and ABI were determined. A Duplex
ultrasound examination to detect restenosis of the target lesion was
performed, and walking capacity was assessed with a questionnaire
(SF-35).
The primary endpoint was defined as improved walking
distance and absence of restenosis.
The local ethics committee (‘‘Kantonale Ethikkommission
Zu¨rich’’) approved the study and all patients gave written
informed consent.
Laboratory measurements
Triglycerides, total cholesterol and lipoprotein cholesterol
values were measured by enzymatic procedures (Abbott ABA
200 instrument). HDL cholesterol was determined by the dextran
sulphate-magnesium precipitation procedure. Low-density lipo-
protein cholesterol was calculated with the Friedewald formula [8].
To assess LDL particles size and distribution, non-denaturing
polyacrylamide gradient gel electrophoresis (GGE) of plasma was
performed at 10–14uC in 2–16% polyacrylamide gradient gels.
Gels were subjected to electrophoresis for 24 h at 125 V in tris
borate buffer (pH 8.3) as described elsewhere [9]. Gels were fixed
and stained for lipids in a solution containing Oil Red O in 60%
ethanol at 55uC. Gels were placed on a light source and
photographed using a Luminescent Image Analyzer, LAS-3000
of Fujifilm. Migration distance for each absorbance peak was
determined and the molecular diameter corresponding to each
peak was calculated from a calibration curve generated from the
migration distance of size standards of known diameter, which
includes carboxylated latex beads (Duke Scientific, Palo Alto, CA),
thyroglobulin and apoferritin (HMW Std, Pharmacia, Piscataway,
NJ) having molecular diameter of 38.0 nm, 17.0 nm and 12.2 nm,
respectively, and lipoprotein calibrators of previously determined
particle size. LDL subclass distribution (LDL I (272–285 nm), IIA
(265–272 nm), IIB (256–265 nm), IIIA (247–256 nm), IIIB (242–
247 nm), IVA (233–242 nm) and IVB (220–233 nm)) as percent-
age of total LDL was calculated.
Ankle-brachial index and Duplex ultrasound
Ankle-brachial arterial pressure index was assessed with the
patient in the supine position. Systolic ankle blood pressure of the
posterior and anterior tibial artery, and the peroneal artery on
both legs was obtained by hand-held 6 MHz Doppler probe
(Kranzbu¨hler, Logidop 2, Pilger Medical Electronics, Switzer-
land). ABI was calculated as the ratio of the highest ankle systolic
blood pressure divided by the highest brachial systolic blood
pressure for each leg. The ABI of the treated leg was taken as the
study parameter.
Patency of the revascularized segment was assesed at three
months follow-up visit with duplex ultrasound (DUS), primary
patency was maintained until restenosis (.50% diameter reduc-
tion) defined by a peak systolic velocity (PSV) ratio .2.4 was
documented by DUS.
Revascularization procedure
All patients were treated according to guidelines with throm-
bocyte antiaggregation and/or anticoagulation, statins, and
antihypertensive therapy if indicated.
In addition to best medical treatment, patients were treated with
balloon angioplasty, stent implantation was additionally performed
at the discretion of the interventionalist. Medication remained
unchanged except for clopidogrel given for a period of 28 days in
case of stent implantation.
Statistical analysis
Data are presented as means 6 SD, or values and percentages.
For the analysis of categorical data, the x2 and Fisher’s exact test
were applied. For comparison of continuous variables in two
independent groups, the Mann–Whitney U test was used. A
generalized linear model was used for the testing of correlations. A
value of p,0.05 was considered significant.
Results
Patient characteristics
A total of 64 patients were included in the study (53.1% males,
mean age 68.669.9 years). Baseline data are summarized in
Table 1. Mean ABI was 0.7160.20. Antiplatelet/anticoagulation
medication at baseline included acetylsalicylic acid (90.6%),
clopidogrel (53.1%), low molecular weight heparin (14.1%) and
oral anticoagulation with phenprocoumon (6.3%). Lipid-lowering
agents (statins) were used in 90.6% of patients. Antihypertensive
medication included diuretics (37.5%), beta-blocker (32.8%),
calcium channel blockers (29.7%), ACE inhibitors (31.3%),
angiotensin II receptor antagonists (26.6%) and aldosterone
receptor antagonists (6.3%).
Most patients were classified as Fontaine stage IIb (50%) and IIa
(21%). Only 6% and 1.2% were staged Fontaine stage I or III,
respectively. Fotaine stages were defined as follows: Stage I -
asymptomatic, incomplete blood vessel obstruction, stage II - mild
claudication pain in limb, stage IIA - Claudication at a distance of
greater than 200 metres, stage IIB - Claudication distance of less
than 200 metres, stage III - rest pain, mostly in the feet, stage IV -
necrosis and/or gangrene of the limb.
Outcome
The combined endpoint of improved walking distance without
occurrence of restenosis was reached in 24 (37.5%) patients with a
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significant improvement of ABI from 0.7060.20 to 0.9361.80
(p,0.002). Restenosis or reocclusion of the treated lesion occurred
in 11 patients. The use of stents (in 39.1% of patients) did not
influence the combined endpoint (reached in 33.3% of patients
without stent implantation and in 44% of patients with stent
implantation, p = 0.44).
LDL size
At baseline, mean LDL particle size was 26.361.1 nM, and did
not differ at follow-up (26.461.0 nM, ns). LDL particle size was
significantly higher in women than in men at both time points
(baseline: 26.661.1 nM vs. 26.061.1 nM, follow-up:
26.660.8 nM vs. 26.161.1 nM, p,0.05). There was no correla-
tion between LDL size and age, but there was a negative
correlation with BMI at follow-up (p = 0.006), and a trend towards
a negative correlation at baseline (p = 0.07).
LDL size at baseline and at follow-up was different between
patients achieving the primary end-point and those who did not.
Patients with improved walking distance and without restenosis
had a significantly higher LDL size at baseline (26.661.1 nM vs.
26.161.1 nM, p=0.046) and at follow-up (26.761.1 nM vs.
26.260.9 nM, p= 0.044, figure 1) than those who did not
improve or restenosed.
LDL particle subclasses
The distribution of different LDL subclasses among patients
which improvement compared to those without improvement at
three months follow-up is shown in figure 2. The proportion of
small dense LDL particles (class III and IV) was significantly lower
in patients who reached the primary end-point compared to those
who did not. These differences were seen at baseline (33.1611.0%
vs. 39.4612.1%, p= 0.038) and at follow-up (39.868.2% vs.
46.8610.1%, p= 0.008). If the components of the primary
endpoint were analyzed separately, a tendency was detected
towards a lower proportion of small dense LDL particles in
patients without restenosis (compared to those with restenosis) at
baseline (36.4611.6% vs. 40.8613.2%, p= 0.30) and at follow-up
(43.1610.2% vs. 48.168.6%, p= 0.09), and a significant differ-
ence was seen in patients with improved walking distance
(compared to those without improvement) at baseline
(33.6611.3% vs. 39.5612%, p= 0.04) and at follow-up
(40.969.1% vs. 46.4610%, p= 0.04).
Using a generalized linear model, the effect of different
cardiovascular risk factors was assessed. The proportion of small,
dense LDL particles at follow-up was still significantly lower in
patients who met the end-point after adjustment for gender,
smoking status and the diagnoses of arterial hypertension,
dyslipidemia or diabetes mellitus (p = 0.03, table 2).
Other cardiovascular risk factors
In addition to the assessment with a generalized linear model,
the individual effect of baseline cardiovascular risk factors – in
particular conventional risk factors – other than LDL size was
further assessed by analyzing differences between the two outcome
groups.
Age was not different in patients who reached the primary end-
point compared to those who did not (67.5610.5 vs. 69.369.5,
p = 0.69), as was BMI (25.464.7 vs. 25.164.0 kg/m2, p= 0.92)
and gender (female gender 58.3% vs. 40.0%, p= 0.20). Further,
there was no difference in the concentration of total cholesterol
(4.761.0 mM vs. 4.561.2 mM, p= 0.57), HDL cholesterol
(1.460.6 mM vs. 1.260.5 mM, p= 0.38), LDL cholesterol
(2.560.6 mM vs. 2.361.0 mM, p= 0.07) or triglycerides
(1.760.9 vs. 2.461.7 mM, p=0.23). Statin therapy was installed
in 90.6% of patients at baseline, and started in the remaining 9.4%
(6 patients) at the time of admission. The primary outcome did not
differ significantly between patients with and without statin
therapy (p= 0.19).
Discussion
The results of this study show that patients with a successful
outcome after percutaneous revascularization of PAD have a
larger LDL particles size compared to patients who fail to show a
Table 1. Baseline characteristics of study population (n = 64).
Characteristic Mean/proportion
Age (years) 69610
Sex male/female (%) 53/47
BMI (kg/m2) 25.264.3
Total cholesterol (mmol/l) 4.661.1
HDL cholesterol (mmol/l) 1.360.6
LDL cholesterol (mmol/l) 2.460.9
Triglycerides (mmol/l) 2.161.4
Coronary artery disease (%) 28
Cerebrovascular disease (%) 31
Renal insufficiency (%) 22
Arterial Hypertension (%) 83
Diabetes mellitus (%) 30
Smoker
Current (%) 48
Ever (%) 80
Values are given in absolute numbers (mean6SD) or as percentage.
doi:10.1371/journal.pone.0108813.t001
Figure 1. LDL particle size in non-successful (restenosis and/or
absence of clinical improvement) vs successful revasculariza-
tion, * p,0.05.
doi:10.1371/journal.pone.0108813.g001
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clinical improvement or who develop restenosis of the treated
vessel. This suggests that small LDL particle size may be used as a
predictor of poor outcome after peripheral angioplasty.
A correlation between some lipid markers such as lipoprotein (a)
or other serum lipid subfractions and restenosis rate after
angioplasty of the peripheral or coronary arteries has already
been shown [10]. However, to our knowledge this is the first study
investigating the impact of the LDL particle size with respect to
restenosis and clinical outcome in claudicants.
Patients with PAD have a high level of small LDL-particles [11],
and are more prone to cardiovascular events [6]. In patients with
coronary stent implantation, an increase in LDL particle size
during follow-up is associated with reduced incidence of in-stent
restenosis [12]. Here we show an association with baseline (and
follow-up) LDL particle size, but not with its changes during
follow-up.
The reasons for the atherogenicity of small LDL particle are
varied and not completely understood, it is thought that the small
particles are absorbed better by the arterial tissue [13]. In addition,
there is probably a greater affinity with the proteoglycans of
connective tissue [14] and greater exposure to oxidative processes
[15]. Furthermore, a correlation of small dense LDL particles with
progressing atherosclerosis has been shown in many studies.
Increased intima media thickness is associated with a smaller LDL
particle size. In addition to these cross-sectional association studies
[16,17], we collected also prospective data showing a predictive
value of the amount of small dense LDL particles at baseline
regarding progression of intima media thickness during a follow-
up of two years in patients with dysglycemia [18].
Angioplasty causes a mechanical vascular injury with induction
of an inflammatory reaction. It is characterized by inflammatory
cell infiltration, release of growth factors, medial smooth muscle
cell (SMC) modulation and proliferation [19]. Therefore, it is
conceivable that all these mechanisms, which lead to neointimal
proliferation, are accelerated by the presence of sdLDL particles.
In contrast to sdLDL particles, there was no association of LDL
cholesterol levels with the primary endpoint, therefore LDL
cholesterol seems not able to predict the outcome of endovascular
intervention. This is probably due to the fact that rigorous LDL
cholesterol control with statins is installed in patients suffering
from PAD. Further, the independence of LDL cholesterol levels
and sdLDL particles is underlined by studies describing different
effects of certain therapies on LDL cholesterol and sdLDL [20].
The GGE method for determination of LDL particle size and
classification has been shown to be reliable, with a high agreement
when compared to other methods. However, it should be
mentioned that there are also other methods as nuclear magnetic
resonance or ion mobility with comparable precision. Further,
newer methods have been developed that are convenient to use
and may help to establish the use of LDL particle size outside the
academic research [21]
The strength of this study is that the data were prospectively
assessed in a well-defined cohort of patients with PAD undergoing
revascularization. Further, due to the single center design of the
study, it was possible that all clinical and biochemical measure-
ments were performed at the same place and by the same
investigators, therefore limiting possible inter-observer biases. This
was of particular importance with respect to the measurement of
LDL size and assessment of restenosis rate. A limitation is the
relatively small sample size.
In summary, the presence of high amounts of small dense LDL
particles is a negative predictor regarding successful outcome of
peripheral angioplasty. Therefore, measurement of this parameter
should be considered in patients undergoing balloon angioplasty.
Further, therapies targeting LDL particle size and the proportion
Figure 2. Relative distribution of the different LDL size
subclasses (from LDL I = large to LDL IV= small) within the
two outcome groups.
doi:10.1371/journal.pone.0108813.g002
Table 2. Multiple linear regression was performed to assess the effect of the amount of small dense LDL particles as well as
gender, smoking status and the diagnoses of arterial hypertension, dyslipidemia or diabetes mellitus on the primary outcome.
95% Confidence Interval
Parameter Coefficient Lower Upper p-Value
sdLDL particles (%) 20.014 20.026 20.001 0.03
Female Gender 0.075 20.156 0.306 0.53
Smoker 0.001 20.225 0.227 0.99
Hypertension 20.142 20.440 0.156 0.35
Dyslipidemia 0.057 20.189 0.304 0.65
Diabetes 20.129 20.380 0.122 0.31
doi:10.1371/journal.pone.0108813.t002
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of sdLDL particles might be considered in patients with high
amounts of sdLDL particles in the future to improve clinical
outcome after vascular intervention.
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